Incidence of cancer in a cohort of patients with primary Sjögren syndrome in Argentina
Primary Sjögren syndrome (pSS) is usually a mild disease, but serious complications such as non-Hodgkin lymphoma—and hypothetically other malignancies—may develop. The aim of this study was to evaluate both overall and specific incidence of cancer in a cohort of patients with pSS compared to the expected incidence in general population of Argentina. Retrospective analytic study of pSS patients fulfilling American-European Consensus Group (AECG) criteria, followed from the time of their diagnosis until the end of the study, death, loss of follow- up, or being given a diagnosis of cancer. Cancer incidence for the general population was obtained from GLOBOCAN 2018, and demographic information was obtained from the national institute for statistics and census. Age- and sex-specific Standardized Incidence Ratio (SIR) were then calculated. One hundred fifty-seven patients, with a mean age of 57.8 years (SD 18.3), were included. Mean patient follow-up duration was 7.37 years (SD 4.2), contributing to a total of 1158 patient/years. Fifteen patients developed a malignancy during follow-up. Cancer incidence for pSS patients was compared with the general population’s incidence through SIRs. Female patient’s SIRs for overall cancer was 4.17 (95% CI 2.30–6.87), non-Hodgkin lymphoma 41.40 (95% CI 10.12–102.1), multiple myeloma 41.49 (95% CI 1.14–167.28), tongue cancer 44.4 (95% CI 1.23–177.31), uterus cancer 8.39 (95% CI 0.19–40.73), lung cancer 4.51 (95% CI 0.1–22.16), and breast cancer 3.76 (95% CI 1.04–9.45). An increased overall cancer risk, and particularly for non-Hodgkin lymphoma, multiple myeloma, breast cancer and tongue cancer was observed in female pSS patients compared to control group.
KeywordsSjogren’s syndrome [D012859] Hematologic neoplasms [D019337] Lymphoma Non-Hodgkin [D008228] Neoplasms [D009369]
We thank Dr. Valeria Scaglioni for her participation in the study design, and BS. Rachel V Lyzak for her help in the improvement of the scientific writing of this manuscript.
Compliance with ethical standards
Conflict of interest
Martin Brom declares that he has no conflict of interest. Sebastian Moyano declares that he has no conflict of interest. Ignacio Javier Gandino declares that he has no conflict of interest. Marina Scolnik declares that she has no conflict of interest. Enrique Roberto Soriano reports grants and personal fees from Roche, grants and personal fees from Novartis, grants and personal fees from Abbvie, grants and personal fees from Glaxo, personal fees from Pfizer, personal fees from Lilly, personal fees from Sanofi, personal fees from AMGEN, personal fees from Bristol Myers Squibb, personal fees from Genzyme, outside the submitted work. All listed authors meet the ICMJE 4 criteria for authorship and have approved the final manuscript. All co-authors take full responsibility for the integrity of the study and the final manuscript. This study has been presented in the 2018 PANLAR meeting, abstract #38 (Brom M, Moyano S, Scolnik M, Gandino JI, Soriano ER (2018) Incidence of Cancer in a cohort of patients with primary Sjögren syndrome. Abstracts, 20th PANLAR Meeting. JCR J Clin Rheumatol 24:S1–S174. https://doi.org/10.1097/RHU.0000000000000802), and in the 2017 ACR meeting, abstract #1483 (Brom M, Moyano S, Scolnik M, Soriano ER (2017) Incidence of Cancer in a Cohort of Patients with Primary Sjögren Syndrome [abstract]. 2017 ACR/ARHP Annual Meeting Abstract Supplement. Arthritis Rheumatol 69:1–4481. https://doi.org/10.1002/art.40321).
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
IRB00010193, protocol number #5141, Comité de Ética de Protocolos de Investigación del Hospital Italiano de Buenos Aires).
Patients sign a general informed consent on their first visit to our institution, authorizing the use of their medical data in an anonymized way for retrospective studies.
- 9.Brito-Zerón P, Acar-Denizli N, Zeher M et al (2017) Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: a cross-sectional study from the big data Sjögren Project consortium. Ann Rheum Dis 76:1042–1050. https://doi.org/10.1136/annrheumdis-2016-209952 CrossRefGoogle Scholar
- 11.Global Cancer Observatory, International Agency for Research on Cancer, World Health Organization Cancer Today. http://gco.iarc.fr/today/home. Accessed 27 July 2019
- 12.Instituto Nacional de Estadísticas y Censos Republica Argentina Proyecciones Nacionales. https://www.indec.gob.ar/indec/web/Nivel4-Tema-2-24-84. Accessed 27 July 2019
- 15.Schenone L, Pellet A, Mamani M et al (2019) Development of lymphoma in patients with primary Sjögren syndromes. Int J Clin Rheumtol 14:69–74Google Scholar
- 16.Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM (1999) Malignant lymphoma in primary Sjögren’s syndrome: a multicenter, retrospective, clinical study by the European concerted action on Sjögren’s syndrome. Arthritis Rheum 42:1765–1772. https://doi.org/10.1002/1529-0131(199908)42:8%3c1765:AID-ANR28%3e3.0.CO;2-V CrossRefGoogle Scholar